| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_241c3d4e236532a2e822eb39f56b1be9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-453
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436 |
| filingDate |
2014-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8aba5406cc70eff9615eb7efc7495e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0bbfed4d54b858472d9373d36657fdd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb8ed8fba8d56f4d9d897caf84ebf621 |
| publicationDate |
2020-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2799185-T3 |
| titleOfInvention |
Therapeutic agent for meibomian dysfunction |
| abstract |
A pharmaceutical composition comprising sirolimus at a concentration of 0.01 to 0.5% (w / v) as the sole active ingredient for use in suppressing the obstruction of the meibomian gland and / or telangiectasia around the orifices of the gland meibomiana, wherein the composition is administered by instillation administration 1 to 2 times per day, and wherein a dosage form for the composition is an eye drop. |
| priorityDate |
2013-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |